ArticlePloS one2013
Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Discovery of natural scaffolds as HER2 inhibitors for breast cancer: virtual screening, molecular dynamics, and biological characterization with selectivity profiling.Scientific reports · 2025Article
- Cancer: A pathologist's journey from morphology to molecular.Medical journal, Armed Forces India · 2022Review
- Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling.Cell reports · 2022Article
- The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization.Diagnostics (Basel, Switzerland) · 2021Review
- Visualisation of HER2 homodimers in single cells from HER2 overexpressing primary formalin fixed paraffin embedded tumour tissue.Molecular medicine (Cambridge, Mass.) · 2019Article
- Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET.The journal of pathology. Clinical research · 2016Article
- Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Laboratory investigation; a journal of technical methods and pathology · 2015Article
- Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells.PloS one · 2015Article
- Molecular pathology - the value of an integrative approach.Molecular oncology · 2014Review
- Immunohistochemistry of colorectal cancer biomarker phosphorylation requires controlled tissue fixation.PloS one · 2014Article
- Hesperetin effect on MLH1 and MSH2 expression on breast cancer cells BT-549.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHER2/Neu (ErbB-2) overexpression, which occurs in 15-20% of breast cancer cases, is associated with better response to treatment with the drug trastuzumab. PhosphoHER2 (pHER2) has been evaluated for prediction of response to trastuzumab. Both markers are heterogeneously detected and are potentially subject to loss as a consequence of delayed time to fixation. Here, we quantitatively assess both markers in core needle biopsies (CNBs) and matched tumor resections to assess concordance between the core and the resection and between HER2 and pHER2.
methodsA selected retrospective collection of archival breast cancer cases yielded 67 cases with both core and resection specimens. Both HER2 and pTyr(1248)HER2 were analyzed by the AQUA® method of quantitative immunofluorescence on each specimen pair.
resultsBoth HER2 immunoreactivity (P<0.0001) and pTyr(1248)HER2 immunoreactivity (P<0.0001) were lower in resections relative to CNB specimens. However, clinical implications of this change may not be evident since no case changed from 3+ (CNB) to negative (resection). Assessment of pTyr(1248)HER2 showed no direct correlation with HER2 in either CNB or resection specimens.
conclusionsThe data suggest that measurement of both HER2 and phospho- Tyr(1248)HER2, in formalin-fixed tissue by immunological methods is significantly affected by pre-analytic variables. The current study warrants the adequate handling of resected specimens for the reproducible evaluation of HER2 and pHER2. The level of pTyr(1248)HER2, was not correlated to total HER2 protein. Further studies are required to determine the significance of these observations with respect to response to HER2 directed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.